<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321930</url>
  </required_header>
  <id_info>
    <org_study_id>WI193025</org_study_id>
    <nct_id>NCT02321930</nct_id>
  </id_info>
  <brief_title>Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients</brief_title>
  <official_title>Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker
      disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and
      whether early MSUS measures/MBDA can predict response to therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline or change in MSUS PDUS score</measure>
    <time_frame>baseline, 1 month, 3 months</time_frame>
    <description>Correlation with change in DAS28, CDAI, and MBDA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline or change in MBDA</measure>
    <time_frame>baseline, 1 month, 3 months</time_frame>
    <description>Correlation with change in DAS28, CDAI, and MBDA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>tofacitinib 5mg po bid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label with tofacitinib 5mg po bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib 5mg po bid</intervention_name>
    <arm_group_label>tofacitinib 5mg po bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must meet 1987 ACR criteria

          2. Age &gt; 18 years of age

          3. Baseline DAS28/ESR&gt;=3.2

          4. Stable concomitant DMARDs

          5. Stable prednisone &lt;10mg or equivalent

          6. Power Doppler score of &gt;=10
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Veena K Ranganath, M.D.,M.S.</last_name>
    <phone>310-825-3061</phone>
    <email>vranganath@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriel Valdivia</last_name>
    <phone>310-794-9504</phone>
    <email>gvaldivia@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veena K Ranganath, M.D.</last_name>
      <phone>310-825-6301</phone>
      <email>vranganath@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Veena K Ranganath, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 26, 2016</lastchanged_date>
  <firstreceived_date>September 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dr. Veena Ranganath</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Musculoskeletal Ultrasound</keyword>
  <keyword>Tofacitinib</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
